Welcome!

News Feed Item

Global MicroRNA Market Report

 

DUBLIN, Apr. 15, 2014
/PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/6zn3pr/global_microrna) has announced the addition of the "Global MicroRNA Market Report" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The analysts forecast the Global MicroRNA market to grow at a CAGR of 17.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in microRNA research funding. The Global MicroRNA market has also been witnessing the discovery and development of microRNAs as biomarkers for diseases. However, the high R&D costs could pose a challenge to the growth of this market.

The report, Global MicroRNA Market Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers North America, Europe, and the ROW; it also covers the Global MicroRNA market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

A biomarker is a substance or a molecular or cellular process or event that indicates a biological condition. Several research studies have confirmed that microRNAs have immense potential as biomarkers for a range of diseases, from cancer to cardiovascular diseases. An increasing number of vendors in the market are focusing on the discovery of microRNA biomarkers for diseases that do not as yet have defined microRNA biomarkers.

For instance, Biogen Idec Inc., a US-based biotechnology company focusing on the development of drugs for the Healthcare sector, and Regulus Therapeutics Inc., a US-based microRNA therapeutics company, have collaborated in their efforts to discover and develop microRNA biomarkers for multiple sclerosis. Thus, the Global MicroRNA market is witnessing the increasing use of microRNAs as biomarkers.

According to the report, one of the most important drivers is the increasing prevalence of diseases such as cancer, which has led to an increase in demand for microRNA-based diagnostic tests.


Key Topics Covered:

01. Executive Summary

02. Scope of the Report

03. Market Research Methodology

04. List of Abbreviations

05. Introduction

06. Market Landscape

07. Global MicroRNA Research Market

08. Global MicroRNA Market

09. Global MicroRNA Market Segmentation

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

19. Key Vendor Analysis

20. Other Reports in this Series


Companies Mentioned:

  • Access Pharmaceuticals
  • Aegera Therapeutics Inc.
  • Affymetrix Inc.
  • Agilent Technologies
  • Alnylam Pharmaceuticals Inc.
  • Antisense Pharma GmbH
  • Aparna Biosciences Corp.
  • Applied Biological Materials Inc.
  • Arrowhead Research Corp.
  • AstraZeneca Pharmaceuticals LP
  • Asuragen Inc.
  • Benitec Biopharma Ltd.
  • BioCancell Therapeutics Inc.
  • Biogen Idec Inc.
  • CBC Comprehensive Biomarker Center GmbH
  • Clontech Laboratories Inc.
  • Dicerna Pharmaceuticals Inc.
  • EMD4Biosciences
  • Eli Lilly and Co.
  • Exiqon A/S
  • Expression Genetics Inc.
  • F. Hoffman-La Roche AG
  • Fluidigm Corp.
  • GeneCopoeia Inc.
  • GenoSensor Corp.
  • Gensignia Inc.
  • GlaxoSmithKline
  • Groove Biopharma
  • HTG Molecular Diagnostics Inc.
  • Idera Pharmaceuticals Inc.
  • Illumina Inc.
  • InteRNA Technologies B.V.
  • Isis Pharmaceuticals Inc.
  • LC Sciences Llc
  • Life Technologies Corp.
  • Merck & Co. Inc.
  • Mirna Therapeutics Inc.
  • NanoString Technologies Inc.
  • Norgen Biotek Corp.
  • Novartis AG
  • Pfizer Inc.
  • Phalanx Biotech Group
  • PhaseRx Inc.
  • Prolias Technologies Inc.
  • Qiagen N.V.
  • Quark Pharmaceuticals Inc.
  • RXi Pharmaceuticals Corp.
  • Regulus Therapeutics Inc.
  • Rosetta Genomics Ltd.
  • Sanofi U.S.
  • Santaris Pharma A/S.
  • Sarepta Therapeutics
  • Sigma-Aldrich Co. Llc
  • Silence Therapeutics Plc
  • Sirnaomics Inc.
  • Sylentis SA
  • Tacere Therapeutics Inc.
  • Tekmira Pharmaceuticals Corp.
  • Theradiag
  • Thermo Fisher Scientific Inc.
  • WaferGen Biosystems Inc.
  • miRagen Therapeutics Inc.
  • siRNAsense AS

For more information visit http://www.researchandmarkets.com/research/6zn3pr/global_microrna

Media Contact: Laura Wood , +353-1-481-1716, [email protected]

 



More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
"Storpool does only block-level storage so we do one thing extremely well. The growth in data is what drives the move to software-defined technologies in general and software-defined storage," explained Boyan Ivanov, CEO and co-founder at StorPool, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Sometimes I write a blog just to formulate and organize a point of view, and I think it’s time that I pull together the bounty of excellent information about Machine Learning. This is a topic with which business leaders must become comfortable, especially tomorrow’s business leaders (tip for my next semester University of San Francisco business students!). Machine learning is a key capability that will help organizations drive optimization and monetization opportunities, and there have been some...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The question before companies today is not whether to become intelligent, it’s a question of how and how fast. The key is to adopt and deploy an intelligent application strategy while simultaneously preparing to scale that intelligence. In her session at 21st Cloud Expo, Sangeeta Chakraborty, Chief Customer Officer at Ayasdi, provided a tactical framework to become a truly intelligent enterprise, including how to identify the right applications for AI, how to build a Center of Excellence to oper...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
As Marc Andreessen says software is eating the world. Everything is rapidly moving toward being software-defined – from our phones and cars through our washing machines to the datacenter. However, there are larger challenges when implementing software defined on a larger scale - when building software defined infrastructure. In his session at 16th Cloud Expo, Boyan Ivanov, CEO of StorPool, provided some practical insights on what, how and why when implementing "software-defined" in the datacent...
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Is advanced scheduling in Kubernetes achievable?Yes, however, how do you properly accommodate every real-life scenario that a Kubernetes user might encounter? How do you leverage advanced scheduling techniques to shape and describe each scenario in easy-to-use rules and configurations? In his session at @DevOpsSummit at 21st Cloud Expo, Oleg Chunikhin, CTO at Kublr, answered these questions and demonstrated techniques for implementing advanced scheduling. For example, using spot instances and co...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.